Abstract
Mycophenolic acid (MPA) is the active part of the corresponding morpholinoethyl ester pro-drug Mycophenolate Mofetil. MPA, an inhibitor of IMP dehydrogenase, depletes GTP and thereby suppresses transfer of mannose and fucose to proteins. Treatment of human monocytes with a clinically attainable concentration of MPA (10 microM) decreases their attachment to endothelial cells and to laminin, but not to type I collagen or fibronectin. Our results not only elucidate a major role of mannose/fucose residues in homing of monocytes on activated endothelium but also explain in part the beneficial effects of MPA in rheumatoid arthritis and organ graft rejection.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antigens, Surface / analysis
-
Carbohydrate Conformation
-
Cell Adhesion / drug effects*
-
Cell Survival / drug effects
-
Collagen / metabolism
-
Cytokines / biosynthesis
-
Endothelium, Vascular / cytology*
-
Enzyme Inhibitors / pharmacology
-
Fibronectins / metabolism
-
Fucose / chemistry
-
Glycoproteins / biosynthesis
-
Glycosylation
-
Humans
-
IMP Dehydrogenase / antagonists & inhibitors
-
Laminin / metabolism
-
Mannose / chemistry
-
Mannosidases / pharmacology
-
Monocytes / chemistry*
-
Monocytes / cytology*
-
Monocytes / drug effects
-
Mycophenolic Acid / pharmacology*
-
Phagocytosis
-
alpha-Mannosidase
Substances
-
Antigens, Surface
-
Cytokines
-
Enzyme Inhibitors
-
Fibronectins
-
Glycoproteins
-
Laminin
-
Fucose
-
Collagen
-
IMP Dehydrogenase
-
Mannosidases
-
alpha-Mannosidase
-
Mycophenolic Acid
-
Mannose